Literature DB >> 30713803

Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors.

Renata Boldrini1, Maria Debora De Pasquale2, Ombretta Melaiu2,3, Marco Chierici4, Giuseppe Jurman4, Maria Chiara Benedetti1, Nunzio C Salfi5, Aurora Castellano2, Paola Collini6, Cesare Furlanello4, Vito Pistoia7, Loredana Cifaldi2, Monica Terenziani8, Doriana Fruci2.   

Abstract

Although pediatric malignant extracranial germ-cell tumors (meGCTs) are among the most chemosensitive solid tumors, a group of patients relapse and die of disease. To identify new markers predicting clinical outcome, we examined the prognostic relevance of tumor-infiltrating T lymphocytes (TILs) and the expression of PD-1 and PD-L1 in a cohort of pediatric meGCTs by in situ immunohistochemistry. MeGCTs were variously infiltrated by T cell-subtypes according to the tumor subtype, tumor location and age at diagnosis. We distinguished three different phenotypes: i) tumors not infiltrated by T cells (immature teratomas and half of the yolk sac tumors), ii) tumors highly infiltrated by CD8+ T cells expressing PD-1, which identifies activated tumor-reactive T cells (seminomas and dysgerminomas), iii) tumors highly infiltrated by CD8+ T cells within an immunosuppressive tumor microenvironment characterized by CD4+FOXP3+ Treg cells and PD-L1-expressing tumor cells (embryonal carcinomas, choriocarcinomas and the remaining yolk sac tumors). Tumor subtypes belonging mixed meGCTs were variously infiltrated, suggesting the coexistence of multiple immune microenvironments either facilitating or precluding the entry of T cells. These findings support the hypothesis that TILs influence the development of meGCTs and might be of clinical relevance to improve risk stratification and the treatment of pediatric patients.

Entities:  

Keywords:  PD-1; PD-L1; Tumor microenvironment; effector T cells; immunohistochemistry; malignant extracranial germ-cell tumor; pediatric cancer; regulatory T cells

Year:  2018        PMID: 30713803      PMCID: PMC6343784          DOI: 10.1080/2162402X.2018.1542245

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  48 in total

1.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

2.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  Activated status of tumour-infiltrating lymphocytes and apoptosis in testicular seminoma.

Authors:  Evgeny Yakirevich; Oleg Lefel; Yanina Sova; Avi Stein; Oded Cohen; Ofer Ben Izhak; Murray B Resnick
Journal:  J Pathol       Date:  2002-01       Impact factor: 7.996

4.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

5.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

6.  Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89.

Authors:  U Göbel; D T Schneider; G Calaminus; H Jürgens; H J Spaar; W Sternschulte; K Waag; D Harms
Journal:  J Clin Oncol       Date:  2001-04-01       Impact factor: 44.544

7.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

8.  Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.

Authors:  Barbara Cushing; Roger Giller; John W Cullen; Neyssa M Marina; Stephen J Lauer; Thomas A Olson; Paul C Rogers; Paul Colombani; Frederick Rescorla; Deborah F Billmire; Charles D Vinocur; Edith P Hawkins; Mary Margaret Davis; Elizabeth J Perlman; Wendy B London; Robert P Castleberry
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

9.  Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells.

Authors:  Sine Reker Hadrup; Otto Braendstrup; Grete Krag Jacobsen; Svend Mortensen; Lars Østergaard Pedersen; Tina Seremet; Mads Hald Andersen; Jürgen C Becker; Per Thor Straten
Journal:  Int J Cancer       Date:  2006-08-15       Impact factor: 7.396

10.  Influence of tumor site and histology on long-term survival in 193 children with extracranial germ cell tumors.

Authors:  A De Backer; G C Madern; R Pieters; P Haentjens; F G A J Hakvoort-Cammel; J W Oosterhuis; F W J Hazebroek
Journal:  Eur J Pediatr Surg       Date:  2008-02       Impact factor: 2.191

View more
  5 in total

1.  Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience.

Authors:  Susan Chi; Kee Kiat Yeo; Chantel Cacciotti; Jungwhan Choi; Sanda Alexandrescu; Mary Ann Zimmerman; Tabitha M Cooney; Christine Chordas; Jessica Clymer
Journal:  J Neurooncol       Date:  2020-07-05       Impact factor: 4.130

Review 2.  Rare Diseases of the Oral Cavity, Neck, and Pharynx.

Authors:  Christoph A Reichel
Journal:  Laryngorhinootologie       Date:  2021-04-30       Impact factor: 1.057

Review 3.  Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes.

Authors:  Claudia Cocco; Fabio Morandi; Irma Airoldi
Journal:  Cells       Date:  2021-04-17       Impact factor: 6.600

4.  Immunotherapies for Pediatric Solid Tumors: A Targeted Update.

Authors:  Ajay Gupta; Timothy P Cripe
Journal:  Paediatr Drugs       Date:  2021-11-25       Impact factor: 3.930

5.  Profiling the 3D interaction between germ cell tumors and microenvironmental cells at the transcriptome and secretome level.

Authors:  Margaretha A Skowron; Katharina Eul; Alexa Stephan; Gillian F Ludwig; Gamal A Wakileh; Arthur Bister; Christian Söhngen; Katharina Raba; Patrick Petzsch; Gereon Poschmann; Edmund Osei Kuffour; Daniel Degrandi; Shafaqat Ali; Constanze Wiek; Helmut Hanenberg; Carsten Münk; Kai Stühler; Karl Köhrer; Elvira Mass; Daniel Nettersheim
Journal:  Mol Oncol       Date:  2022-07-26       Impact factor: 7.449

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.